VERTEX PHARMACEUTICALS INC / MA (VRTX) /
The cash flow of VERTEX PHARMACEUTICALS INC / MA over the past 10 years
Chart VERTEX PHARMACEUTICALS INC / MA: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, VERTEX PHARMACEUTICALS INC / MA's operating cash flow was $3.63B and its capital expenditures $437.6M, leaving free cash flow of $3.19B. Free cash flow was above zero in 9 of the 10 years shown. It ranged from -$790.3M in fiscal 2024 to $3.93B in fiscal 2022. Capital expenditures were highest in fiscal 2025, at $437.6M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $3.63B | $437.6M | $3.19B |
| 2024ended Dec 31, 2024 | -$492.6M | $297.7M | -$790.3M |
| 2023ended Dec 31, 2023 | $3.54B | $200.4M | $3.34B |
| 2022ended Dec 31, 2022 | $4.13B | $204.7M | $3.93B |
| 2021ended Dec 31, 2021 | $2.64B | $235M | $2.41B |
| 2020ended Dec 31, 2020 | $3.25B | $259.8M | $2.99B |
| 2019ended Dec 31, 2019 | $1.57B | $75.4M | $1.49B |
| 2018ended Dec 31, 2018 | $1.27B | $95.45M | $1.17B |
| 2017ended Dec 31, 2017 | $844.94M | $99.42M | $745.52M |
| 2016ended Dec 31, 2016 | $236.1M | $56.56M | $179.54M |
Fiscal years as VERTEX PHARMACEUTICALS INC / MA reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on VERTEX PHARMACEUTICALS INC / MA
- The revenue of VERTEX PHARMACEUTICALS INC / MA
- The profitability of VERTEX PHARMACEUTICALS INC / MA
- The debt of VERTEX PHARMACEUTICALS INC / MA
- All of VERTEX PHARMACEUTICALS INC / MA's financials, charted
Companies of a similar size
- SPGIS&P Global Inc.
- PGRPROGRESSIVE CORP/OH/
- UBERUber Technologies, Inc
- FTNTFORTINET, INC.
- LMTLOCKHEED MARTIN CORPORATION
Not investment advice. This page shows what VERTEX PHARMACEUTICALS INC / MA filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.